{"organizations": [], "uuid": "096d3d3d06d1ccc39d454cf2157bace9f38727fa", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180216.html", "section_title": "Archive News &amp; Video for Friday, 16 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-ablynx-announces-option-exercise-b/brief-ablynx-announces-option-exercise-by-sanofi-to-license-two-additional-target-combinations-idUSFWN1Q6038", "country": "US", "domain_rank": 408, "title": "BRIEF-Ablynx Announces Option Exercise By Sanofi To License Two Additional Target Combinations​", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.218, "site_type": "news", "published": "2018-02-16T15:20:00.000+02:00", "replies_count": 0, "uuid": "096d3d3d06d1ccc39d454cf2157bace9f38727fa"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-ablynx-announces-option-exercise-b/brief-ablynx-announces-option-exercise-by-sanofi-to-license-two-additional-target-combinations-idUSFWN1Q6038", "ord_in_thread": 0, "title": "BRIEF-Ablynx Announces Option Exercise By Sanofi To License Two Additional Target Combinations​", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "sanofi", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 16 (Reuters) - ABLYNX NV:\n* ABLYNX ANNOUNCES OPTION EXERCISE BY SANOFI FOR TWO ADDITIONAL MULTI-SPECIFIC NANOBODY PRODUCT CANDIDATES\n* SANOFI HAS EXERCISED ITS OPTION TO LICENSE TWO ADDITIONAL TARGET COMBINATIONS​\n* ‍OPTION AS PART OF RESEARCH COLLABORATION SIGNED IN JULY 2017​\n* ‍SANOFI GAINS EXCLUSIVE GLOBAL RIGHTS TO TWO ADDITIONAL MULTI-SPECIFIC NANOBODIES AGAINST SELECTED TARGETS​\n* ‍IN RETURN SANOFI WILL PAY ABLYNX EXERCISE FEES TOTALLING EUR 13 MILLION PLUS ADDITIONAL RESEARCH FUNDING​\n* ‍ABLYNX HAS ALREADY RECEIVED AN UPFRONT PAYMENT TOTALLING EUR 23 MILLION\n* ‍RECEIVED AN UPFRONT PAYMENT IS TOGETHER WITH RESEARCH FUNDING UNDER THIS COLLABORATION​\n* ‍SANOFI WILL BE RESPONSIBLE FOR DEVELOPMENT, MANUFACTURING AND COMMERCIALISATION OF ANY PRODUCTS RESULTING FROM THIS AGREEMENT​\n* ‍ABLYNX WILL BE ELIGIBLE TO RECEIVE DEVELOPMENT, REGULATORY AND COMMERCIAL MILESTONE PAYMENTS OF UP TO EUR 2.4 BILLION PLUS TIERED ROYALTIES​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-16T15:20:00.000+02:00", "crawled": "2018-02-17T14:26:21.003+02:00", "highlightTitle": ""}